May 17th 2024
Second-line venetoclax may lead to monthly cost savings vs second-line BTK inhibitor for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
NX-5948 Gets FDA Fast Track Designation for Relapsed/Refractory CLL/SLL
January 18th 2024A fast track designation has been granted by the FDA to the novel BTK degrader, NX-5948, for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with at least two lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.
Newly Diagnosed Ph+ CML Derives MMR Benefits With Asciminib vs SOC TKIs
January 17th 2024Treatment with asciminib for newly diagnosed, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase induced statistically significant and clinically meaningful major molecular response benefits compared with standard-of-care TKIs.
Pirtobrutinib Generates Durable Responses in CLL/SLL After BTKi Therapy
December 11th 2023The use of pirtobrutinib following covalent Bruton tyrosine kinase inhibitor therapy may be an important sequencing approach in chronic lymphocytic leukemia/small lymphocytic lymphoma, according to recent research.
Telephone Intervention Reduces Unplanned Hospitalizations for Patients With Blood Cancers
April 30th 2015A navigator-designed, proactive, weekly, telephone support call to help patients with blood cancers manage their symptoms between appointments was able to significantly reduce unplanned hospitalizations at a Colorado cancer center.